Since the overexpression of EZH2 is associated with more aggressive tumor behavior and poorer patient outcomes in osteosarcoma, we performed a proliferation assay to determine whether EZH2 silencing could inhibit cell growth. The gene discussed is EZH2; the disease is neoplasm.